GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Debt-to-Asset

Inventiva (Inventiva) Debt-to-Asset : 0.54 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Inventiva Debt-to-Asset?

Inventiva's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.79 Mil. Inventiva's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $35.09 Mil. Inventiva's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $75.86 Mil. Inventiva's debt to asset for the quarter that ended in Dec. 2023 was 0.54.

Inventiva Debt-to-Asset Historical Data

The historical data trend for Inventiva's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva Debt-to-Asset Chart

Inventiva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.07 0.08 0.30 0.54

Inventiva Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.17 0.30 0.50 0.54

Competitive Comparison of Inventiva's Debt-to-Asset

For the Biotechnology subindustry, Inventiva's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inventiva's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Inventiva's Debt-to-Asset falls into.


Inventiva Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Inventiva's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5.788 + 35.094) / 75.857
=0.54

Inventiva's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5.788 + 35.094) / 75.857
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva  (NAS:IVA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Inventiva Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Inventiva's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Inventiva (Inventiva) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Debt-to-Asset
Comparable Companies
XPAR:AELIS XPAR:IPH XPAR:DBV XPAR:MEDCL XPAR:NANO XPAR:GNFT XPAR:TNG XPAR:ALSEN XPAR:ADOC XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IVA:France 6IV:Germany
Address
50 rue de Dijon, Daix, FRA, 21121
Website
https://www.inventivapharma.com
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.